Get the Stockscreener App
5.63
2.93%
0.16
Nervgen Pharma Corp stock is traded at $5.63, with a volume of 125.88K.
It is up +2.93% in the last 24 hours and up +0.00% over the past month.
NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291 and NVG-300.
See More
Previous Close:
$5.47
Open:
$5.53
24h Volume:
125.88K
Relative Volume:
11.47
Market Cap:
$445.97M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.00%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$5.36
$5.70
1-Week Range:
$5.10
$5.9299
52-Week Range:
$5.10
$5.9299
Nervgen Pharma Corp Stock (NGEN) Company Profile
Compare NGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NGEN
Nervgen Pharma Corp
|
5.63 | 433.29M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Nervgen Pharma Corp Stock (NGEN) Latest News
NervGen Pharma Advances NVG-291 for Spinal Cord Injury Treatment - MSN
NervGen Pharma Begins Trading on Nasdaq Today - Sahm
Is NervGen Pharma Corp. (9UA) stock good for wealth creationJuly 2025 Movers & Weekly High Conviction Trade Ideas - Улправда
NervGen Pharma Debuts On Nasdaq - Nasdaq
NervGen Pharma to Begin Trading on Nasdaq - marketscreener.com
NervGen Pharma Lists on Nasdaq to Support Late-Stage Push for Spinal Cord Injury Drug - TipRanks
NervGen Pharma Gets Approval for Listing on Nasdaq - marketscreener.com
NervGen Pharma Brief: Begins Trading on Nasdaq Today - marketscreener.com
This Company’s Drug May Help Regenerate Injured Spinal Cords - Forbes
NervGen Pharma Announces Filing of Form F-10 Registration Statement with The SEC Under MJDS - Yahoo Finance
NervGen Pharma Proposes Amendment to Warrant Terms - TipRanks
This Canadian biotech stock is looking to treat spinal cord injuries - Cantech Letter
NervGen Pharma’s NVG-291 Shows Promising Results in Spinal Cord Injury Treatment - TipRanks
NervGen Pharma Secures $10M to Propel Nasdaq Listing and NVG-291 Development - TipRanks
NervGen Pharma Announces US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development - Yahoo Finance
Is NervGen Pharma (CVE:NGEN) In A Good Position To Invest In Growth? - Yahoo Finance
Pennsylvania man says experimental drug has helped him recover from cycling accident - CBS News
Nervgen Pharma’s NVG-291 Study: A Potential Breakthrough in Spinal Cord Injury Treatment - TipRanks
NervGen Pharma price target chopped at Research Capital - Cantech Letter
NervGen: A High-Stakes Bet on a Groundbreaking Nerve Repair Drug - NAI500
TSX Penny Stocks To Consider In August 2025 - Yahoo Finance
NervGen Pharma's NVG-291-R Demonstrates Significant Functional Recovery in Department of Defense-Sponsored Preclinical Models of Traumatic Hearing Loss and Peripheral Nerve Injury - Yahoo Finance
NervGen Pharma is a buy, Research Capital says - Cantech Letter
NervGen Pharma Establishes Multiple Sclerosis Clinical Advisory Board - TMX Newsfile
NervGen Announces Leadership Transition to Support Strategic Growth and Expansion - Yahoo Finance
NervGen Strengthens Board Leadership to Accelerate Clinical and Corporate Growth - Yahoo Finance
NervGen Announces Clinical Leadership Transition as NVG-291 Continues to Advance Toward Late-Stage Development and Regulatory Milestones - Yahoo Finance
Insights on NervGen Pharma’s Positive Phase 1b/2a Data for NVG-291 in Spinal Cord Injury - NeurologyLive
NervGen Pharma: Risky, Yet Promising With Big Upside - Seeking Alpha
TSX Penny Stocks To Watch In June 2025 - Yahoo Finance
Leaders in health care innovation - BNN Bloomberg
NervGen Pharma Reports Positive Topline Data from the Chronic Cohort of its Phase 1b/2a Clinical Trial Evaluating NVG-291 in Spinal Cord Injury - Yahoo Finance
NervGen Pharma to Present Topline Data for NVG-291 Phase 1b/2a Chronic Cohort Study at the American Spinal Injury Association Annual Scientific Meeting - Yahoo Finance
NervGen Pharma Reports Q1 2025 Financial Results and Provides Operational Updates - Yahoo Finance
NGENFNervgen Pharma Corp Latest Stock News & Market Updates - Stock Titan
NervGen Pharma is a high-risk, high-reward stock, analyst says - Cantech Letter
NervGen Initiates Expanded Access Policy - Yahoo Finance
Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury - Business Wire
Repairing Spinal Cord Injury Damage - the-scientist.com
Spinal Cord Injury Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Epidemiology, Therapies and Companies by DelveInsight - The Globe and Mail
Undercovered Dozen: OppFi, PowerFleet, Eletrobras, American Battery + - Seeking Alpha
NervGen: Data For Spinal Cord Injury Treatment Candidate Likely For Mid-2025 - Seeking Alpha
NervGen Pharma: Proof that NVG-291 works? | 2024-12-23 | Investing News - Stockhouse
NervGen Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference - TMX Newsfile
Repairing the Spine: Q&A with Mike Kelly, CEO of NervGen - PharmExec.com
NervGen Pharma Appoints Neil Klompas to Board of Directors - TMX Newsfile
NervGen: Are amazing human trial results leaking out? | 2024-07-02 | Investing News - Stockhouse
NervGen Pharma | Biotechnology | The Pharmaletter - The Pharma Letter
Nervgen Pharma advances evaluation of NVG-300 - BioWorld MedTech
NervGen Pharma to Advance NVG-300 into Preclinical Proof-of-Concept Stage - Yahoo Finance
Is This Pharma Co. the Next Eli Lilly? - streetwisereports.com
Nervgen Pharma Corp Stock (NGEN) Financials Data
There is no financial data for Nervgen Pharma Corp (NGEN). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
4.73%
0.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):